cAMP-response element-binding protein (CREB) Extracellular signal-regulated kinase (ERK) Janus kinase (JAK) Myeloid cell leukemia-1 (Mcl-1) 3-nitropropionic acid (3-NP) signal transducer and activator of transcription (STAT) Oncostatin M (OSM), a cytokine in the interleukin-6 (IL-6) family, has been proposed to play a protective role in the central nervous system, such as attenuation of excitotoxicity induced by N-methyl-D-aspartate (NMDA) and glutamate. However, the potential neuroprotective effects of OSM against mitochondrial dysfunction have never been reported. In the present study, we tested the hypothesis that OSM may confer neuronal resistance against 3-nitropropionic acid (3-NP), a plant toxin that irreversibly inhibits the complex II of the mitochondrial electron transport chain, and characterized the underlying molecular mechanisms. We found that OSM preconditioning dose-and time-dependently protected cortical neurons against 3-NP toxicity. OSM stimulated expression of myeloid cell leukemia-1 (Mcl-1), an anti-apoptotic Bcl-2 family member expressed in differentiating myeloid cells, that required prior phosphorylation of Janus kinase-1 (JAK1), JAK2, extracellular signal-regulated kinase-1/2 (ERK1/2), signal transducer and activator of transcription-3 (STAT3), STAT1, and cAMP-response elementbinding protein (CREB). Pharmacological inhibitors of JAK1, JAK2, ERK1/2, STAT3, STAT1, and CREB as well as the siRNA targeting at STAT3 and Mcl-1 all abolished OSM-dependent 3-NP resistance. Finally, OSM-dependent Mcl-1 induction contributed to the enhancements of mitochondrial bioenergetics including increases in spare respiratory capacity and ATP production. In conclusion, our findings indicated that OSM induces Mcl-1 expression via activation of ERK1/2, JAK1/2, STAT1/3, and CREB; furthermore, OSM-mediated Mcl-1 induction contributes to bioenergetic improvements and neuroprotective effects against 3-NP toxicity in cortical neurons. OSM may thus serve as a novel neuroprotective agent against mitochondrial dysfunction commonly associated with pathogenic mechanisms underlying neurodegeneration.
Introduction
Oncostatin M (OSM), a cytokine belongs to the interleukin-6 (IL-6) family, has been shown to play critical roles in inflammation, hematopoiesis, and cellular proliferation [1, 2] . Upon binding to its receptor, OSM triggers two major signaling cascades: the Janus kinase (JAK)/ Signal transducer and activator of transcription (STAT) and the mitogen-activated protein kinases (MAPK) pathways [1, 2] . Following activation of JAKs, predomiantly JAK1 and JAK2, OSM may induce STAT1, STAT3, and STAT5 [3] . Moreover, evidence has shown that phosphorylation of STAT3 at Tyr-705 by JAK2 activates its transcriptional activity, whereas phosphorylation of Ser-727 by ERK1/2 maximizes transcriptional ability of STAT3 in a variety of in vitro models [4, 5] . Thus, the extents of STAT3 phosphorylation, either at Tyr-705 alone by JAK2 or in combination with phosphorylation at Ser-727 by ERK1/2, may serve as an index for its biological activities.
Myeloid cell leukemia-1 (Mcl-1) was initially identified as an immediate-early gene expressed in differentiating myeloid cells [6] [7] [8] . Nowadays, it is also known as a regulator for neuronal development [9] . Mcl-1 contains Bcl-2 homology-1 (BH1), BH2, and BH3 domains, which are important for apoptosis regulation, as well as a C-terminal transmembrane domain that targets Mcl-1 to mitochondrial outer membrane [10] . In addition, Mcl-1 is also involved in mitochondrial energy metabolisms and ATP production [11] . The N-terminal regions of Mcl-1 contain two Proline/Glutamic acid/Serine/Threonine (PEST) domains often found in proteins with rapid turnover rates and, indeed, Mcl-1 has a short half-life that is typically in the range of one to a few hours [8, 12] . The rapid turnover of Mcl-1 is mainly regulated via ubiquitindependent proteasomal degradation [13] . Evidence has demonstrated that Mcl-1 is highly inducible by a variety of cytokines and growth factors; the upstream regulatory kinase cascades of Mcl-1 transcription include MAPKs, phosphatidylinositol-3 (PI3K), and JAK/STAT [7] .
In the central nervous system (CNS), major producers of OSM include microglia, reactive astrocytes, and infiltrating leukocytes [14, 15] . Several lines of evidence have suggested that OSM may also play a role in CNS disorders [16, 17] . For example, OSM pretreatment may offer neuroprotective function against excitotoxicity induced by N-methyl-D-aspartate (NMDA) and glutamate [18, 19] . However, the potential neuroprotective effects of OSM against mitochondrial dysfunction have never been reported. In the present study, we tested the hypothesis that OSM may confer neuronal resistance against 3-nitropropionic acid (3-NP), a plant toxin that irreversibly inhibits the complex II of the mitochondrial electron transport chain leading to energy impairment [20] , and characterized the underlying molecular mechanisms. Furthermore, we also investigated whether OSM may affect the mitochondrial respiratory function and bioenergenics by measuring the oxygen consumption rate (OCR) in cortical neurons.
Materials and methods

Reagents
3-NP (Cat. No. 73803, Sigma, St. Louis, MO, USA) was dissolved in phosphate-buffered saline (PBS) as a stock solution of 1 M and adjusted to pH 7.4 with 10 M sodium hydroxide. The 3-NP stock solution was then dispensed into 1-ml aliquots, protected from light, and stored at − 20°C until use. Recombinant rat OSM (Cat. No. 400-36, Peprotech, Rocky Hill, NJ, USA) and cycloheximide (CHX; Cat. No. C7698, Sigma) were reconstituted in sterile ddH 2 O to make stock solutions of 100 μg/ml and 20 mg/ml before storage at −20°C and 4°C, respectively, until use. AG490 (the JAK2/3 inhibitor; Cat. No. 658401, Calbiochem, La Jolla, CA, USA), ruxolitinib (the JAK1/2 inhibitor; Cat. No. tlrl-rux, InvivoGen, San Diego, CA, USA), PD98059 (the ERK1/2 inhibitor; Cat. No. 513000, Calbiochem), stattic (the STAT3 inhibitor; Cat. No. ab120952, Abcam, Cambridge, MA, USA), SP600125 (the JNK inhibitor; Cat. No. 420119, Calbiochem), oligomycin (the ATP synthase inhibitor; Cat. No. sc-201551, Santa Cruz Biotechnology, Inc., Dallas, TX, USA), and antimycin A (the mitochondrial complex III inhibitor; Cat. No. A8674, Sigma) were dissolved in dimethyl sulfoxide (DMSO; Cat. No. JTB-9033-04; Capitol Scientific, Inc., Austin, TX, USA) as stock solutions of 10 mM, 20 mM, 10 mM, 50 mM, 10 mM, 25 mM, and 25 mM, respectively, before storage at −20°C. KG501 (CREB inhibitor; Cat. No. 70485, Sigma) and carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP; the proton ionophore; Cat. No. C2929, Sigma) were both dissolved in DMSO as a stock solution of 10 mM and 25 mM, respectively, and stored at 4°C until use. S14-95 (STAT1 inhibitor; Cat. No. ALX-350-299-MC05, Enzo Life Sciences, Inc., Farmingdale, NY, USA) was dissolved in methanol as a stock solution of 20 mM and then stored at − 20°C. Preparation of Aβ25-35 was based on our published paper [21] . Briefly, Aβ25-35 (Cat. No. A4559, Sigma) was dissolved in autoclaved ddH 2 O to make a stock solution of 2 mM, dispensed into aliquots, and immediately stored at −80°C until use. One day prior to experimentation, aliquots of Aβ25-35 were incubated at 37°C for 24 h to allow aggregation.
Primary fetal rat cortical cultures
All the procedures for animal care and preparation of fetal rat cortical cultures were carried out humanely in accordance with the guidelines described in the "User Manual of Laboratory Animal Center at National Yang-Ming University". Primary cortical neurons were cultured from embryonic day 18 (E18) fetal Sprague-Dawley (SD) rat brains according to the protocols previously described [22, 23] . The cultures were maintained in the neurobasal medium supplemented with B27 (GIBCO/Invitrogen Corporation) at 37°C in a humidified incubator with 5% CO 2 . Cortical cells were used for experiments between daysin-vitro (DIV) 7-9. The cortical culture used in the present study was a neuron-enriched co-culture system as evidenced by more cells immunostained with antibodies recognizing microtubule-associated protein-2 (MAP-2; approximately 85%) than with glial fibrillary acidic protein (GFAP; approximately 5-15%), the respective cellular marker for neurons and astrocytes [22] .
Hoechst staining for cell survival assays
Counting of Hoechst-stained nuclei with normal nuclear morphology to quantitatively assess the extent of cell survival was described in details in our previous publications [24, 25] . The "Cell Survival (%)" in figures was defined as the mean numbers of surviving cells in experimental groups divided by those of control cultures in the same experiment and then multiplied by 100%.
Real-time RT-PCR
Extraction of total RNA from cortical cultures, reverse transcription for cDNA synthesis, and real-time polymerase chain reaction (PCR) for the detection of Mcl-1 expression at mRNA levels were all performed as previously described [24] . The primers used in current study were: 5′-CGTAACAAACTGGGGCAGGA-3′ (forward) and 5′-AACCCATCCCAG CCTCTTTG-3′ (reverse) for Mcl-1; 5′-GCGAGATCCCGCTAACATCA-3′ (forward) and 5′-CTAAGCAGTTGGTGGTGCAG-3′ (reverse) for glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Primer pairs had been blasted to avoid annealing to non-specific sequences during amplification. After cycling, a melting curve was produced by slow denaturation of the PCR end-products to validate the specificity of amplification. GAPDH was included to serve as an internal reference for normalization of amplification efficiency. 9106, Cell Signaling Technology; 1:1000) were also used. The conditions of hybridization, signal detection, and quantification of signal intensities on the immunoblots were all performed as previously described [26, 27] .
Western blotting
Immunocytochemistry and confocal microscopy
The same rabbit antibodies against STAT3 (1:100), p-STAT3 at Ser-727 (1:50) and Mcl-1 (1:100) for Western blotting were also used for Fig. 1 . OSM preconditioning protects cortical neurons against 3-NP toxicity. (A, B) Rat cortical cultures were pretreated with OSM for 24 h at indicated concentrations (A) or 100 ng/ml OSM for indicated times (B) followed by exposure to 2.5 mM 3-NP or empty medium for additional 24 h. The extents of cell survival were quantitatively assessed by Hoechst staining. Mean ± S.E.M. from N = 4 in (A) and N = 3 in (B). * and # denote P b 0.05. The "ns" denotes "not significant". (C) Rat cortical cultures were pretreated with 100 ng/ml OSM for 24 h followed by exposure to 3-NP at indicated concentrations or empty medium for additional 24 h. The extents of cell survival were quantitatively assessed by Hoechst staining. Mean ± S.E.M. from N = 4. * and # denote P b 0.05. (D) Rat cortical cultures were pretreated with or without 100 ng/ml OSM for 24 h prior to incubation with 2.5 mM 3-NP or in the empty medium for additional 24 h. Immunocytochemistry combined with Hoechst staining (blue) was then conducted to examine the morphology of mature neurons and astrocytes, using MAP-2 (red) and GFAP (green) as the respective protein marker. Scale bar = 20 μm. Note the significantly damaged neuronal morphology by 3-NP (3-NP) that was markedly restored by OSM preconditioning (OSM + 3-NP).
immunocytochemistry. The mouse monoclonal antibody against MAP-2 (Cat. No. MAB378, 1:150, CHEMICON International, Inc., Temecula, CA, USA) and the rabbit polyclonal antibody against GFAP (Cat. No. Z0334, 1:600, DakoCytomation Denmark A/S, Denmark) were applied to stain neurons and astrocytes, respectively. The goat anti-mouse IgG Dylight 594-conjugated secondary antibodies (1:100; excitation: 596 nm/emission: 617 nm; Cat No. GTX76719, GeneTex, Inc., Irvine, CA, USA) and goat anti-rabbit IgG HylightFluor 488-labeled secondary antibodies (1:100; excitation: 499 nm/emission: 523 nm; Cat No. 61056-H488, AnaSpec, Inc., San Jose, CA, USA) were applied to respectively recognize the MAP-2 and GFAP primary antibodies. For confocal microscopy, the coverslips were observed under a laser scanning confocal microscope (Zeiss LSM700; Oberkochen, Germany) equipped with filter sets to detect the corresponding fluorescence signals.
Chromatin immunoprecipitation (ChIP) assay
The ChIP assay was performed using the MangaChIP TM G (Cat.
No. 17-611, Millipore) according to the manufacturer's protocols. Briefly, primary cortical cultures were washed with 1 × PBS and then crosslinked with 1% paraformaldehyde at room temperature for 15 min, which was followed by addition of the glycine supplied in the kit for 5 min. Cells were then washed twice with PBS and then collected in the PBS with protease inhibitor supplied in the kit. Following extraction of nuclei, chromatin DNA was shorn by sonication under the condition of 2-sec pulse-on and 1-sec pulseoff, processed for a total of 2 min on ice. The same STAT3 antibody for Western blotting was used in the ChIP assay. Equal amounts of nuclear proteins (100 μg) were incubated with 20 μl beads and 1 μg rabbit primary antibody against STAT3 or 1 μg normal rabbit IgG at 4°C overnight with rotation. Thereafter, the samples were sequentially washed by Low-Salt Buffer, High-Salt Buffer, LiCl Buffer, and TE Buffer for 5 min each on ice with shaking before addition of Elution Buffer with protease K. Samples were incubated at 62°C for 2 h with shaking followed by incubation at 95°C for 10 min. The immunoprecipitated DNA was purified through the Fast-Spin Column provided in the kit and then subject to PCR for quantification. 
Transfection of siRNAs into primary cortical neurons
Transfection of siRNAs for the knockdown of specific genes in primary cortical neurons was conducted as previously described [23] . The 
Measurement of cellular oxygen consumption
To determine the cellular bioenergetics, the oxygen consumption rate (OCR) was measured by a XF24 Extracellular Flux Analyzer (Seahorse Bioscience, Billerica, MA) [28] [29] [30] [31] . Primary cortical cultures were seeded at a density of 60,000 cells per well on Seahorse XF-24 plates coated with poly-D-lysine and cultured as described above. Subsequent to experimental manipulations, the culture medium was replaced with pre-warmed DMEM medium (Cat. No. 12800, Life technology; DMEM base medium supplemented with 25 mM glucose, 1 mM sodium pyruvate, 110 mM NaCl, 4 mM L-glutamine, pH 7.4) and incubated at 37°C in a non-CO 2 incubator for 1 h before the extracellular flux analysis [28] . Mitochondrial function was quantitatively assessed with sequential injections of oligomycin (the ATP synthase inhibitor), FCCP (the proton ionophore), and antimycin A (the mitochondrial complex III inhibitor), each was diluted in pre-warmed DMEM medium with the final concentration at 1 μM. Four baseline measurements of OCR were determined before injection of mitochondrial inhibitors, and three OCR readings were recorded after addition of each of the above inhibitors. The parameters as indices of mitochondrial function were automatically recorded and calculated by the Seahorse XF-24 software.
Statistical analysis
Results are expressed as Mean ± S.E.M. from the sample numbers (N). For counting of Hoechst-stained surviving cells, the N represents data collected from one independent experiment using one cortical culture. Each independent experiment contained 3 coverslips for every experimental condition. On each coverslip, 3-4 vision fields were randomly selected for counting to obtain the average numbers of surviving cells in each vision field. The mean numbers of surviving cells for each independent experiment were therefore derived from a total of 9-12 vision fields out of 3 coverslips for the same experimental condition. For Western blotting, real-time RT-PCR, and ChIP assay showing quantitative results, each N represents data collected from one experiment using one culture; combined data from at least 3 independent using 3 different cultures are shown. For all the double immunofluorescence staining (Figs. 1C, 2D, 5C, 6G, 7F, 8E), representative images from 3 independent experiments using 3 different cultures are shown. For quantitative determination of OCR without prior siRNA transfection (Fig. 9B-F) , combined results derived from 10 (control) and 12 (OSM) measurements out of 4 different cultures are shown. In Fig. 9G and H, combined results from 5-7 measurements out of 3 different cultures for each experimental condition are shown. Multiple groups were analyzed by one-way analysis of variance (ANOVA) followed by a post-hoc Student-Newman-Keuls test; two groups were analyzed by Student's t-test. P-values of less than 0.05 were considered significant.
Results
Neuroprotective effects of OSM preconditioning against 3-NP toxicity
We first tested whether OSM may afford neuroprotection against mitochondrial inhibition induced by 3-NP. Our results indicated that pretreatment of cortical cultures with OSM at 25-100 ng/ml for 24 h resulted in concentration-dependent cytoprotective effects against 3-NP at 2.5 mM [32] ; the optimal protective effect of OSM was observed at 100 ng/ml (Fig. 1A) . At this dosage, OSM also conferred 3-NP resistance to cortical cells time-dependently, exhibiting the maximal efficacy after 24 h of preconditioning (Fig. 1B ). We then further tested the protective effects of OSM preconditioning against 3-NP at lower concentrations. Results indicated that 3-NP at 0.5-2.5 mM exerted dose-dependent cytotoxicity towards cortical cultures; OSM preconditioning for 24 h also showed the tendency of cytoprotection against 3-NP at 1.5 mM, albeit achieving a marginal statistical significance at P = 0.051 (Fig. 1C) . Possibly due to weaker cytotoxic potency of 3-NP at 0.5 mM, the protective This was followed by treatment with or without 100 ng/ml OSM for 24 h and exposure to 2.5 mM 3-NP or empty medium for additional 24 h. Hoechst staining was conducted to determine the extents of cell survival. Mean ± S.E.M. from N = 3. * and # denote P b 0.05. The "ns" denotes "not significant". (C) Rat cortical cultures were incubated in 100 ng/ml OSM for 24 h followed by exposure to 2.5 mM 3-NP or empty medium for additional 8 h before detection of Mcl-1. Mean ± S.E.M. from N = 4. * and # denote P b 0.05. The "ns" denotes "not significant". effect of OSM preconditioning was not prominent at this condition (Fig. 1C) . In addition to quantitative assessment for cell survival by Hoechst staining, confocal microscopy also revealed OSM-dependent restoration of neuronal morphology from the 3-NP-induced injuries (Fig. 1D ). Based on these findings, preconditioning of cortical cultures with 100 ng/ml OSM for 24 h followed by exposure to 3-NP at 2.5 mM for additional 24 h was selected as the main experimental paradigm for most of the subsequent experiments.
In addition to 3-NP that directly inhibit mitochondrial function, we also tested whether the observed protective effects of OSM preconditioning can be extended to other types of neurotoxins. Amyloid betapeptide (Aβ) is the major neurotoxic component in the senile plaques observed in the brains of Alzheimer's disease (AD) patients [33, 34] . The synthetic Aβ25-35 is also known to cause mitochondrial dysfunction [35] . We therefore also explored potential cytoprotective actions of OSM against Aβ25-35. Results indicated that OSM preconditioning for 24 h significantly, albeit partially, protected cortical cultures against Aβ25-35 toxicity ( Supplementary Fig. 1A ). Thus, OSM-mediated protective effect is not restricted to the complex II inhibitor 3-NP; rather, it can also be applied to other neurotoxic insults capable of inducing mitochondrial inhibition, like Aβ. However, Mcl-1 siRNA failed to suppress the OSM-dependent cytoprotection against Aβ25-35, suggesting involvements of additional factors other than Mcl-1 ( Supplementary  Fig. 1B ). Rat cortical cultures were exposed to 100 ng/ml OSM with or without 50 μM PD98059 or 50 μM AG490 for 24 h before detection of Mcl-1. Mean ± S.E.M. from N = 5. * and # denote P b 0.05. (E) Cultures were exposed to 100 ng/ml OSM with 0.5 μM ruxolitinib or the same amount of the solvent DMSO for 24 h before detection of Mcl-1. Mean ± S.E.M. from N = 3. * and # denote P b 0.05. The "ns" denotes "not significant". (F-H) Primary rat cortical cultures were exposed to 100 ng/ml OSM along with 50 μM PD98059 (F), 50 μM AG490 (G), or 0.5 μM ruxolitinib (H) for 24 h; the solvent DMSO served as negative controls for these pharmacological inhibitors. After OSM preconditioning with or without inhibitors, cortical cultures were challenged with 2.5 mM 3-NP or incubated in empty medium for additional 24 h before Hoechst staining to determine the extents of cell survival. Mean ± S.E.M. from N = 3 in (F), (G), and (H). * and # denote P b 0.05. The "ns" denotes "not significant".
Effects of OSM on Mcl-1 expression in cortical neurons
To identify the key protective mediators downstream of OSM, we first examined the expression patterns of several anti-apoptotic proteins following OSM treatment. Results indicated that, during an episode of 24-h exposure, OSM at 100 ng/ml failed to alter the expression levels of Bcl-2 ( Supplementary Fig. 2A ) and Bcl-xL ( Supplementary  Fig. 2B ) in rat cortical cultures. In addition, OSM pretreatment also failed to alter the extents of caspase-3 cleavage in cortical cultures exposed to 3-NP ( Supplementary Fig. 2C ). Despite lack of evidence linking OSM directly to the induction of Mcl-1, DNA microarray analysis has previously revealed that OSM modulates the expression of Mcl-1, along with other Bcl-2 family members including Bax, Bad, Bnip3, and Bcl-2, in osteosarcoma cells [36] . Further, OSM belongs to the IL-6 family, whereas Mcl-1 is known to be regulated by IL-6 in human myeloma cells [37, 38] . Therefore, we determined whether OSM may affect the expression profile of Mcl-1 in cortical neurons. Results showed that OSM exposure significantly increased expression of Mcl-1 at mRNA levels, beginning at 2 h and lasted until 24 h (Fig. 2A) . Thus, expression of Mcl-1 mRNA is subject to transcriptional regulation by OSM. We then analyzed the expression pattern of Mcl-1 proteins. OSM treatment time-dependently increased Mcl-1 expression, reaching approximately 2 folds of the control level after 24 h (Fig. 2B) . After an episode of 24-h exposure, OSM at 5-200 ng/ml also dose-dependently enhanced the expression of Mcl-1, achieving the maximal extent at 100 ng/ml (Fig. 2C) .
Considering our cortical cultures are a neuron-enriched co-culture system containing both neurons and astrocytes [22] , we further identified the cell types expressing Mcl-1 upon OSM stimulation. Double immunofluorescence staining, using MAP-2 and NeuN as the respective marker of neuronal dendrites and nucleus, revealed that Mcl-1 expression in the cytoplasm of the MAP-2-and NeuN-positive cells was enhanced after 24-h exposure to OSM (Fig. 2D) , indicative of neuronal expression of this protein upon OSM stimulation.
Mcl-1 is known to have a short half-life [10] . Therefore, in addition to transcriptional regulation we also examined whether OSM may affect the protein stability of Mcl-1. Using the protein synthesis inhibitor cycloheximide, we found that the half-lives of Mcl-1 with and without OSM treatment were approximately 1.48 h and 1.86 h, respectively; however, statistical significance of the difference was not achieved (Fig. 2E) . Therefore, OSM does not modulate Mcl-1 stability, suggesting that transcriptional regulation may be the prime mechanism by which OSM increases the expression level of Mcl-1 in rat cortical neurons.
Critical role of OSM-induced Mcl-1 in its neuroprotective effects against 3-NP
Despite its roles as an anti-apoptotic protein possessing beneficial function, whether Mcl-1 mediates the neuroprotective effects of OSM against 3-NP-induced mitochondrial dysfunction remained to be clarified. To address this issue, we determined the effects of Mcl-1 knockdown on OSM-dependent 3-NP resistance in cortical neurons. We first confirmed that the siRNA targeting at Mcl-1 gene, but not the negative control siRNA with scrambled sequences, effectively suppressed its expression induced by OSM (Fig. 3A) . Consistently, knockdown of Mcl-1 by siRNA also completely abolished OSM-dependent 3-NP resistance without affecting cell survival when the cortical cells were exposed to either OSM or 3-NP alone (Fig. 3B) . In addition to Mcl-1 induction by OSM alone, we also explored the combined effects of OSM and 3-NP on the expression level of Mcl-1. Results revealed that Mcl-1 induction by OSM pretreatment for 24 h lasted until at least 8 h after removal of this cytokine (OSM ; Fig. 3C ); challenge with 3-NP alone for 8 h without prior exposure to OSM (3-NP) significantly decreased Mcl-1 expression as compared with both control (Ctrl) or OSM-treated (OSM) cultures (Fig. 3C) . Interestingly, OSM preconditioning for 24 h maintained the expression level of Mcl-1, at least to the extent of control culture, despite subsequent 3-NP exposure for 8 h (OSM + 3-NP; Fig. 3C ).
These findings together indicated that OSM preconditioning prevents declined Mcl-1 expression caused by 3-NP, thereby maintaining the basal level of this protein. Together with the above results using siRNA-mediated knockdown, our findings indicated that such maintenance of cellular Mcl-1 levels by OSM preconditioning is critical for the observed 3-NP resistance in rat cortical neurons.
JAK1, JAK2, and ERK1/2 are involved in OSM-mediated Mcl-1 induction and neuroprotection
Since robust evidence has shown that JAK/STAT and MAPK are the two major signaling cascades triggered by OSM [1, 2] , we first Fig. 5 . Effects of OSM on STAT3 phosphorylation, nuclear translocation, and protein expression. (A, B) Primary cortical cultures were exposed to 100 ng/ml OSM for indicated times before detection of phosphor-STAT3 at Tyr-705 or Ser-727 as well as total STAT3. Mean ± S.E.M. from N = 3-4 in both (A) and (B). * denotes P b 0.05 compared with the corresponding control cultures. (C) Rat cortical cultures were treated with 100 ng/ml OSM or empty medium for 16 h. This was followed by immunocytochemistry combined with Hoechst staining (blue) to observe expression of specific proteins: STAT3 (green) and MAP-2 (red) in the upper panels as well as phosphor-STAT3 at Ser-727 (green) and NeuN (red) in the lower panels. Upper panels: scale bar = 5 μm; lower panels: scale bar = 10 μm. (D) Cortical cultures were exposed to 100 ng/ml OSM with or without PD98059 or AG490 at indicated concentrations in μM for 15 min. This was followed by detection of phosphor-STAT3 at Tyr-705 or Ser-727 as well as total STAT3. Representative blots from 2 independent experiments using 2 different cultures are shown. Note that AG490 partially blocked STAT3 phosphorylation at Tyr-705, whereas PD98059 in part inhibited STAT3 phosphorylation at Ser-727. (E) Cortical cultures were exposed to 100 ng/ml OSM with or without 0.5 μM ruxolitinib for 15 min before detection of phosphor-STAT3 at Tyr-705 and total STAT3. Representative blots from 3 independent experiments using 3 different cultures are shown. Note that ruxolitinib completely blocked STAT3 phosphorylation at Tyr-705. (F) Rat cortical cultures were exposed to 100 ng/ml OSM for indicated times before detection of total STAT3 by Western analysis. Mean ± S.E.M. from N = 3. * denotes P b 0.05 compared with controls.
determined the OSM effects on the phosphorylation status of JAK2, JAK1, and ERK1/2 in cortical cultures. We found that JAK2 was phosphorylated after 5 min of OSM exposure; JAK2 phosphorylation reached approximately 1.5 folds as compared to the controls at 15 min and returned to basal level after 60-min exposure to OSM (Fig. 4A) . In addition, a transient increase of JAK1 phosphorylation was observed after 5 min of OSM exposure, reaching the maximal extent at approximately 25 folds at 15 min and rapidly declined thereafter at 60 min (Fig. 4B) . In addition to JAK1 and JAK2, ERK1/2 was also phosphorylated after 5 min of OSM exposure and this ERK1/2 phosphorylation lasted until 60 min (Fig. 4C) . These above results indicated rapid phosphorylation, and hence activation, of JAK1, JAK2, and ERK1/2 within 5 min following exposure to OSM. However, transient phosphorylation of these kinases does not causally support their crucial roles in mediating the observed Mcl-1 induction and neuroprotection of OSM. Pharmacological studies using the JAK2/3 inhibitor AG490, the ERK1/2 inhibitor PD98059, and Primary rat cortical cultures were treated with 100 ng/ml OSM or empty medium for 1 h and 16 h before ChIP assays. Immunoprecipitation was conducted using 1 μg STAT3 antibody as described in Materials and methods. The same amount of normal rabbit IgG served as the negative control for immunoprecipitation. For PCR reactions, two sets of primers were designed; one was employed to amplify the sequence containing the predicted STATx-binding site and another for the non-STATxbinding site. PCR reactions using the genomic DNA without prior immunoprecipitation as the template and the primer pair designed for non-STATx-binding site were conducted to serve as the positive control (PC). Mean ± S.E.M. from N = 3. * denotes P b 0.05 compared with the corresponding control cultures. (C) Rat cortical cultures were exposed to 100 ng/ml OSM with or without 5 μM stattic, the STAT3 inhibitor, for 24 h before detection of Mcl-1. Mean ± S.E.M. from N = 3. * and # denote P b 0.05. The "ns" denotes "not significant". (D) Primary rat cortical cultures were transfected with 0.1 μM STAT3 (STAT3) siRNA or scrambled (sc) siRNA for 72 h during DIV4-7. This was followed by exposure to 100 ng/ml OSM for additional 24 h before detection of phosphor-STAT3 at Tyr-705 or Ser-727 as well as total STAT3. Representative immunoblots are shown in the upper left panel. Relative expression levels of total STAT3 normalized to β-actin are shown in the bar graph of upper right panel. The cellular contents of phosphor-STAT3 at Tyr-705, also normalized to β-actin, are shown in the bar graph of lower left panel. The extents of STAT3 phosphorylation at Tyr-705 that were normalized to total STAT3 are shown in the bar graph of lower right panel. Mean ± S.E.M. from N = 3-4. *, #, and § all denote P b 0.05. The "ns" denotes "not significant". (E) Primary rat cortical cultures were transfected with 0.1 μM STAT3 (STAT3) siRNA or scrambled (sc) siRNA or 72 h during DIV 4-7. This was followed by exposure to 100 ng/ml OSM for 24 h before detection of Mcl-1. Mean ± S.E.M. from N = 3. *, #, and § all denote P b 0.05. (F) The transfection conditions for siRNAs were the same as described above in (E). At the completion of transfection, cortical cultures were treated with or without 100 ng/ml OSM for 24 h followed by exposure to 2.5 mM 3-NP or empty medium for additional 24 h. Hoechst staining was then conducted to determine the extents of cell survival. Mean ± S.E.M. from N = 3. *, #, and § all denote P b 0.05. (G) The experimental conditions were identical to (F) except that immunocytochemistry combined with Hoechst staining (blue) were conducted to observe the morphology of mature neurons and astrocytes. MAP-2 (red) and GFAP (green) were used as the respective protein marker for mature neuronal dendrites and astrocytes. Scale bar = 20 μm. Note that the STAT3 siRNA effectively neutralized OSM-mediated 3-NP resistance. Fig. 6 (continued) . the JAK1/2 inhibitor ruxolitinib were therefore conducted. As a result, partial inhibition of OSM-induced Mcl-1 expression by both AG490 and PD98059 was noted (Fig. 4D) , whereas ruxolitinib completely abrogated OSM-mediated Mcl-1 induction (Fig. 4E) . Further, coincubation of OSM with PD98059 (Fig. 4F), AG490 (Fig. 4G ), or ruxolitinib (Fig. 4H) during the preconditioning phase all significantly abolished OSM-dependent neuroprotective effects against 3-NP. Together, results shown in Fig. 4 revealed critical involvements of JAK1, JAK2, and ERK1/2 in mediating OSM-induced Mcl-1 expression and 3-NP resistance.
In addition to JAK1, JAK2, and ERK1/2, we also investigated possible involvements of other kinases including Akt and JNK. Our results indicated that OSM did not significantly affect the phosphorylation status of Akt ( Supplementary Fig. 2A ) and JNK ( Supplementary Fig. 2B) ; furthermore, the JNK inhibitor SP600125 at 20 μM failed to inhibit OSMinduced Mcl-1 expression ( Supplementary Fig. 2C ). These findings further strengthened the specificity of JAK1, JAK2, and ERK1/2 in contributing to OSM-dependent Mcl-1 induction and neuroprotection.
JAK/ERK-dependent phosphorylation of STAT3 and induction of STAT3 protein by OSM
Next, we examined the potential OSM effects on the phosphorylation status of STAT3, a well-established transcription factor downstream of JAKs. Robust evidence has shown that biological activities of STAT3 are attributable to its phosphorylation, either at Tyr-705 by JAK2 or at Ser-727 by ERK1/2 [4, 5] . Our results revealed that short-term (0-60 min; Fig. 5A ) as well as long-term (0-24 h; Fig. 5B ) exposure to OSM time-dependently increased the extents of STAT3 phosphorylation at both Tyr-705 and Ser-727. OSM treatment for 5 min induced phosphorylation of STAT3 at Tyr-705, achieving the maximal level at 4 h (approximately 20 folds of the control level) and lasted until 24 h (Fig. 5A  and B) . For the phosphorylated STAT3 at Ser-727, similar results were observed, albeit to a much lesser extent as compared to Tyr-705 phosphorylation (approximately 2 folds of the control level; Fig. 5A, B) . Phosphorylation of STAT3 is expected to result in nuclear translocation to activate the expression of its target genes. Double immunofluorescence staining revealed that OSM treatment enhanced the nuclear contents of total STAT3 and the phosphor-STAT3 at Ser-727 in the MAP-2-and NeuN-positive cells, respectively (Fig. 5C ), indicating nuclear localization of STAT3 in neurons upon OSM stimulation.
To elucidate the correlations between JAK1/JAK2/ERK1/2 and the phosphorylation status of Tyr-705/Ser-727 in STAT3, cortical cultures were exposed to OSM for 15 min along with the pharmacological inhibitors each targeting at a specific kinase. Results showed partial suppression of STAT3 phosphorylation at Tyr-705 by 200 μM and 250 μM AG490, the JAK2/3 inhibitor, whereas STAT3 phosphorylation at Ser-727 was significantly abolished by 150 μM PD98059, the ERK1/2 inhibitor (Fig. 5D) . Notably, STAT3 phosphorylation at Tyr-705 was completely abolished by the JAK1/2 inhibitor ruxolitinib (Fig. 5E) . Thus, JAK1 and JAK2 participate in STAT3 phosphorylation at Tyr-705, while ERK1/2 is involved in STAT3 phosphorylation at Ser-727 (Fig. 5D, E) . In addition to the OSM effects on STAT3 phosphorylation, we found that the expression level of total STAT3 was also increased after 16-h and 24-h exposure to OSM (Fig. 5F ). Thus, OSM regulates STAT3 activity via at least two distinct mechanisms, namely enhancing its phosphorylation at Tyr-705 and Ser-727 via activation of JAK1, JAK2, and ERK1/2 as well as increasing total cellular contents of STAT3 proteins.
STAT3 directly participates in OSM-dependent Mcl-1 induction and neuroprotection
To further explore whether STAT3 directly binds to the promoter region of Mcl-1 gene upon OSM exposure, ChIP assay was conducted. The predicted binding sites for STATs and the positions of primer pairs used in ChIP assays are depicted in Fig. 6A . Results indicated that OSM exposure for 1 h and 16 h both enhanced STAT3 binding to the Mcl-1 promoter (Fig. 6B) . To rule out any potential false-positive signal, one pair of primers was also designed to amplify the DNA sequence within the promoter of Mcl-1 that was predicted to be outside the STAT-binding sites. As expected, no signal can be detected by ChIP assay using this primer pair amplifying the non-STATx-binding sequence, either with or without OSM treatment for 1 h; this was not due to failure of PCR reaction as genomic DNA without prior immunoprecipitation can be successfully amplified (Fig. 6B) . Once the OSM-dependent enhancement of STAT3 binding to the Mcl-1 promoter was confirmed, we then characterized potential involvement of STAT3 in OSM-dependent Mcl-1 induction and neuroprotection. Stattic is a non-peptide small molecule that can selectively inhibit STAT3 function by blocking its SH2 domain and interrupting its dimerization [39] . Results shown in Fig. 6C indicated that stattic at 5 μM [40, 41] completely abolished OSM-induced Mcl-1 expression. For gene-specific knockdown, we first confirmed that STAT3 siRNA fully suppressed the OSM-induced STAT3 expression down to the control level, despite the increased total STAT3 proteins (immunoblots in Fig. 6D ). Further, this siRNA also diminished the amounts of phosphor-STAT3 at both Tyr-705 and Ser-727 (immunoblots in Fig. 6D ). Quantitative analyses of signal intensities on these blots confirmed the efficacy of siRNA in knocking down STAT3 expression (upper right bar graph in Fig. 6D ). However, the siRNA failed to downregulate STAT3 phosphorylation at Tyr-705 (lower right bar graph in Fig. 6D ) and Ser-727 (quantitative data not shown) when normalized to total STAT3. Although the STAT3 siRNA at best partially reduced the cellular contents of phosphor-STAT3 at Tyr-705 (lower left bar graph in Fig. 6D ) and Ser-727 (quantitative data not shown) when normalized to β-actin, it still suppressed, albeit partially, the expression of OSM-induced Mcl-1 (Fig. 6E) and OSM-dependent neuroprotection against 3-NP toxicity based on Hoechst staining (Fig. 6F) and immunocytochemistry (Fig. 6G) .
STAT1 participates in OSM-mediated Mcl-1 induction and neuroprotection
In addition to STAT3 phosphorylation, we also examined the effects of OSM on the phosphorylation status of STAT1, which is another typical transcription factor downstream of JAK. As shown in Fig. 7A , short-term (0-60 min) treatment of OSM time-dependently increased the extents of STAT1 phosphorylation at Tyr-701, reaching approximately 10 folds at 15 min (bar graph); however, long-term (0-24 h) incubation of OSM failed to stimulate Tyr-701 phosphorylation of STAT1, unlike those observed for STAT3 at Tyr-705 and Ser-727 (Fig. 5B) . STAT1 phosphorylation at Tyr-701 induced by 15-min exposure of OSM was in part suppressed by AG490 at both 200 μM and 250 μM, but not by PD98059 at 150 μM (Fig. 7B) . However, ruxolitinib at 0.5 μM exerted a much stronger effect in abolishing OSM-mediated STAT1 phosphorylation at Tyr-701, leading to complete inhibition (Fig. 7C ) that was similar to those results observed for STAT3 at Tyr-705 (Fig. 5E ). These findings indicated that JAK1 and JAK2, but not ERK1/2, participate in STAT1 phosphorylation at Tyr-701 induced by OSM (Fig. 7B, C) .
To explore the potential involvement of STAT1 in OSMdependent Mcl-1 induction and neuroprotection, pharmacological studies employing its selective inhibitor were conducted. S14-95 is Fig. 7 . Roles of STAT1 in OSM-induced Mcl-1 expression and neuroprotection. (A) Primary cortical cultures were exposed to 100 ng/ml OSM for indicated times (short-term: 0-60 min; long-term: 0-24 h) before detection of phosphor-STAT1 at Tyr-701 and total STAT1. Quantitative analyses of the signal intensities on the immunoblots of short-term OSM exposure (0-60 min) are shown in the bar graph. Mean ± S.E.M. from N = 3. * denotes P b 0.05 as compared with control. (B) Cortical cultures were exposed to 100 ng/ml OSM with or without PD98059 or AG490 at indicated concentrations in μM for 15 min before detection of phosphor-STAT1 at Tyr-701 and total STAT1. Representative blots from 2 independent experiments using 2 different cultures are shown. Note that phosphorylation of STAT1 at Tyr-701 was abolished by AG490, but not by PD98059. (C) Cortical cultures were exposed to 100 ng/ml OSM with or without 0.5 μM ruxolitinib for 15 min before detection of phosphor-STAT1 at Tyr-701 and total STAT1. Representative blots from 3 independent experiments using 3 different cultures are shown. Note that ruxolitinib completely abolished OSM-induced STAT1 phosphorylation at Tyr-701. (D) Cortical cultures were exposed to 100 ng/ml OSM with 20 μM S14-95, the STAT1 inhibitor, or the same amount of methanol, its solvent, for 24 h before detection of Mcl-1. Mean ± S.E.M. from N = 3. * and # denote P b 0.05. The "ns" denotes "not significant". (E, F) Primary rat cortical cultures were treated with 100 ng/ml OSM with 20 μM S14-95 or methanol for 24 h; this was followed by exposure to 2.5 mM 3-NP or empty medium for additional 24 h. In (E), cells were subject to Hoechst staining to determine the extents of cell survival. Mean ± S.E.M. from N = 3. *, #, and § all denote P b 0.05. In (F), immunocytochemistry combined with Hoechst staining (blue) were conducted to observe the morphology of mature neurons and astrocytes. MAP-2 (red) and GFAP (green) served as the respective protein marker for mature neuronal dendrites and astrocytes. Scale bar = 20 μm. Note that OSM preconditioning rescued cortical neurons from 3-NP-mediated neurite fragmentation, whereas S14-95 reversed this OSM-dependent neuroprotective effects. a potent inhibitor derived from Penicillium that can functionally inhibit STAT1α [42, 43] . Results shown in Fig. 7D indicated that S14-95 at 20 μM [42, 43] fully suppressed OSM-induced Mcl-1 expression down to the basal level. In addition, S14-95 at this dosage in part abolished the protective effect of OSM against 3-NP based on Hoechst staining (Fig. 7E) and immunocytochemistry (Fig. 7F) .
CREB participates in OSM-mediated Mcl-1 induction and neuroprotection
Previous studies have shown that CREB is implicated in IL-3 activation of Mcl-1 expression [44] . More importantly, we also identified potential binding sites of CREB on the promoter region of rat Mcl-1 gene (Fig. 6A) . Therefore, possible participation of CREB on the OSM effects was also investigated. We found that OSM transiently increased the extents of CREB phosphorylation at Ser-133, reaching the maximal extent at 2-4 h and declined thereafter (Fig. 8A) . PD98059 fully suppressed OSM-dependent CREB phosphorylation back to the control level (Fig. 8B) , indicating that ERK1/2 acts upstream of CREB phosphorylation induced by OSM. Indeed, PD98059 also decreased the basal level of CREB phosphorylation even in the absence of OSM stimulation (Fig. 8B) . KG501 is a small-molecule antagonist capable of inhibiting CREB pathway through the interference of CREB-CBP (CREB-binding protein) interaction to attenuate target gene induction triggered by cAMP [45] . We found that KG501 at 10 μM completely abolished OSM-induced Mcl-1 expression; at this dosage KG501 also showed the tendency of attenuating the expression of the endogenous Mcl-1, but statistical significance was not achieved (Fig. 8C) . Consistently, KG501 abolished the protective effect of OSM against 3-NP in rat cortical neurons based on Hoechst staining (Fig. 8D) and immunocytochemistry (Fig. 8E) .
Roles of Mcl-1 in OSM-dependent enhancement of mitochondrial respiratory functions
We have revealed a novel and complex signaling cascade of OSMdependent Mcl-1 induction and neuroprotection against 3-NP, which is a complex II inhibitor known to compromise the mitochondrial function, in cultured cortical neurons. However, the potential impacts of OSM preconditioning and subsequent induction of Mcl-1 on mitochondrial bioenergetics remain undefined. The capacity of mitochondrial respiration can be measured by the changes of oxygen consumption rate (OCR) triggered by the sequential addition of oligomycin, FCCP, and antimycin A. These parameters including basal respiration, ATP production, proton leak, maximal respiration rate, spare respiratory capacity, and non-mitochondrial respiration may thus serve as functional indices for the status of mitochondrial bioenergetics in cultured cells [46] . Therefore, to address the issues of OSM effects on mitochondrial functions, we measured the OCRs in the cortical neurons subjected to various experimental manipulations. Fig. 9A demonstrates a representative result showing the real-time detection of OCR following addition of each mitochondrial inhibitor. The basal OCR of the mitochondrial respiration was detected before the injection of oligomycin. We found that the OCRs of basal respiration were significantly higher in OSM-treated cultures as compared to those in the control cultures (Fig. 9B) . To determine the maximal respiration rate a cell can sustain, the uncoupler FCCP was injected following addition of oligomycin. Results indicated that the maximal respiration rate of OSM-treated cultures were significantly higher than the control cultures (Fig. 9C) . The spare respiratory capacity is a potential diagnostic index of the bioenergetics for neurons under environmental stress [46, 47] . Our results indicated that OSM considerably enhanced the spare respiratory capacity in primary cortical cultures (Fig. 9D) . Consistently, the extents of ATP production were also higher in OSM-treated cultures (Fig. 9E) while no significant difference in non-mitochondrial respiration was detected between the two groups (Fig. 9F) . Together, results shown in Fig. 9A -F strongly support the contention that OSM pretreatment may enhance mitochondrial bioenergetics in primary cortical neurons. However, whether this OSM effects involve induction of Mcl-1 was unknown. To answer this question, Mcl-1 siRNA was transfected into cortical cultures to knock down its expression. Results indicated that OSMinduced increases in spare respiratory capacity (Fig. 9G ) and ATP production (Fig. 9H) were both suppressed by Mcl-1 siRNA, but not the scrambled negative control siRNA. Indeed, Mcl-1 siRNA alone attenuated endogenous spare respiratory capacity (Fig. 9G) , but not the ATP production despite this tendency (Fig. 9H) . Taken together, results shown in Fig. 9 suggest that OSM enhances mitochondrial bioenergetics in cultured cortical neurons in vitro via the induction of Mcl-1, at least in part.
Discussion
While it was initially purified and characterized based on the antiproliferative activity in human melanoma cell line in vitro [48] , OSM has now been proposed to play important roles in the CNS [1, 2] . These include suppressing proliferation of the neural precursor cells (NPCs) in subventricular zones of adult brains [49] and supporting normal development of nociceptive neurons in dorsal root ganglia [50] . Apart from its functions in the development of nervous systems, potential neuroprotective effects of OSM have been noted. For example, OSM is a powerful protective cytokine that neutralizes excitotoxic injuries, both in vitro and in vivo, via inhibiting NMDA-mediated increase in free intracellular calcium ions and selectively reducing neuronal expression of the NR2C subunit of NMDA receptor [18] . Further, OSM protection of cultured neurons against glutamate-induced excitotoxicity requires neuronal adenosine A1 receptor [19] . In another study, OSM protects primary cortical neurons derived from embryonic mice against the deprivation of B27, a vital supplement for growth and differentiation of primary neurons; however, detailed mechanisms were not reported in that study [51] . In this work, we delineated a novel and complex signal transduction pathway involving JAK1, JAK2, ERK1/2, STAT1, STAT3, and CREB, which together lead to Mcl-1 induction and 3-NP resistance as a result of OSM preconditioning; furthermore, OSM-induced Mcl-1 contributes to 3-NP resistance in part via enhancement of mitochondrial respiration and ATP production (Fig. 10) .
In current study, pretreatment of cortical cultures with OSM at 100 ng/ml for 24 h showed optimal protective efficacy against 3-NP neurotoxicity based on Hoechst staining (Fig. 1A, B) and immunocytochemical staining with neuronal marker MAP-2 (Fig. 1D) . OSM under the same experimental conditions also significantly, albeit partially, protected cortical cultures against neurotoxicity mediated by Aβ25-35 ( Supplementary Fig. 1 ). In the experimental model of B27 deprivation, the protective efficacy was observed in primary mouse cortical neurons treated with OSM at 500 ng/ml, but not at 50 or 5 ng/ml, for 72 h in a cotreatment paradigm; further, incubation with OSM at 50 ng/ml for 72 h also enhanced neurite outgrowth [51] . Also in mouse cortical neurons, preconditioning with 1 ng/ml OSM for 24 h in part attenuated glutamate-induced excitotoxicity [19] . While the rationales underlying these different neuroprotective dosages of OSM among the previous studies and our own work are not clear yet, the discrepancy may be Fig. 8 . Roles of CREB in the OSM-dependent Mcl-1 expression and neuroprotection. (A) Rat cortical cultures were exposed to 100 ng/ml OSM for indicated times before detection of phosphor-CREB at Ser-133 and total CREB. Mean ± S.E.M. from N = 3. * denotes P b 0.05 compared with control culture. (B) Cortical cultures were exposed to 100 ng/ml OSM with or without 50 μM PD98059 for 2 h before detection of phosphor-CREB at Ser-133 and total CREB. Mean ± S.E.M. from N = 3. * and # denote P b 0.05. The "ns" denotes "not significant". (C) Cortical cultures were exposed to 100 ng/ml OSM with or without 10 μM KG501 for 24 h before detection of Mcl-1. Mean ± S.E.M. from N = 3. * and # denote P b 0.05. The "ns" denotes "not significant". (D, E) Rat cortical cultures were exposed to 100 ng/ml OSM with or without 10 μM KG501 for 24 h; this was followed by challenge with 2.5 mM 3-NP for additional 24 h. In (D), cells were subject to Hoechst staining to determine the extents of cell survival. Mean ± S.E.M. from N = 3. * and § denote P b 0.05. The "ns" denotes "not significant". In (E), immunocytochemistry combined with Hoechst staining (blue) was conducted to observe the morphology of mature neurons and astrocytes. MAP-2 (red) and GFAP (green) were used as the respective protein marker for mature neuronal dendrites and astrocytes. Scale bar = 20 μm. Note that OSM preconditioning rescued cortical neurons from 3-NP-mediated neurite fragmentation, whereas KG-501 markedly reversed this OSM-dependent neuroprotective effects.
attributed to several factors including differences in cell types, treatment times, cell survival assays, and selection of experimental paradigms such as pretreatment or cotreatment. Despite distinct underlying mechanisms in different models, all these findings point to the neuroprotective potential of OSM in the CNS.
The longer preconditioning time required for optimal protective effects of OSM observed in this work is also interesting. Previously we have reported that primary cortical cultures pretreated with brain-derived neurotrophic factor (BDNF) for 8 h are more resistant to neurotoxicity caused by subsequent 3-NP exposure [32] . In the present study, however, the optimal preconditioning time for OSM was observed at 24 h (Fig. 1B) , substantially longer as compared to BDNF preconditioning that takes only 8 h to achieve the maximal protective effect [32] . In another two studies, OSM pretreatment for 24 h was also the most efficacious condition counteracting excitotoxicity induced by NMDA [18] and glutamate [19] , consistent with our findings (Fig. 1B) . Two possible reasons may be considered. First, although heightened expression of the key protective factor Mcl-1 was observed as early as 2 h after OSM exposure, it reached higher levels at 24 h (Fig. 2B) . Second, we found that total STAT3 expression was also increased after 16-24 h exposure to OSM (Fig. 5 F) with sustained STAT3 phosphorylation at Tyr-705 and Ser-727 until 24 h (Fig. 5B) . Indeed, similar OSM effects in stimulating STAT3 expression and continued STAT3 phosphorylation were observed in vivo in the retina via intravitreal injection with OSM. In that report, apart from STAT3 phosphorylation at Tyr-705 that was prominent as early as 30 min and lasted for 48 h following administration of OSM, heightened expression of STAT3 was also detected at 12-48 h post-injection [52] . Thus, OSM preconditioning may stimulate continued STAT3 activation via at least two distinct mechanisms, namely sustained phosphorylation of STAT3 at Tyr-705/Ser-727 as well as increased expression of total STAT3 proteins, thereby together contributing to the maintenance of higher levels of Mcl-1 with resultant neuroprotective effects against 3-NP toxicity. Interestingly, OSM also appeared to increase the cellular contents of STAT1 proteins after longer exposure for 8-24 h (Fig. 7A) . However, it is less likely that heightened STAT1 expression contributed to the OSM-dependent long-term induction of Mcl-1. This is because, in our paradigm, OSM failed to induce sustained phosphorylation of STAT1 at Tyr-701 (Fig. 7A) .
In addition to distinct roles of various STAT proteins in mediating OSM-dependent Mcl-1 induction, various JAK proteins also play a differential role. AG490 is known to inhibit both JAK2 and JAK3 but not JAK1, whereas ruxolitinib may suppress both JAK1 and JAK2 while sparing JAK3 [53] . In current study, we found that ruxolitinib completely abolished OSM-mediated STAT3 phosphorylation at Tyr-705 (Fig. 5E) , STAT1 phosphorylation at Tyr-701 (Fig. 7C) , and Mcl-1 induction (Fig. 4E) . However, AG490 at best partially inhibited these OSM effects (Figs. 4D, 5D, 7B) . Moreover, we found that the maximal extent of JAK1 phosphorylation stimulated by OSM was markedly greater than that of JAK2 phosphorylation (25 folds for JAK1 in Fig. 4B versus 1 .5 folds for JAK2 in Fig. 4A ). Therefore, these results appear to suggest participation of both JAK1 and JAK2, in which JAK1 may play a more dominant role in the observed OSM effects.
Phosphorylation of STAT3 at distinct amino acid residues by specific kinases plays a critical role in transducing its downstream signaling cascades. For example, STAT3 phosphorylation at Tyr-705 is required for its biological activation, whereas phosphorylation at Ser-727 may further enhance its activity [4, 5] . In general, STAT3 phosphorylation at Tyr-705 is JAK-dependent and Ser-727 phosphorylation of STAT3 is mainly regulated by MAPKs or Akt [4, 5, 54] . In addition, studies have revealed that both phosphorylated sites of STAT3 are required for its activity in rat hippocampal neurons in response to transient depolarization, in which STAT3 phosphorylation at Tyr-705 depends on JAK while Ser-727 is mediated by Akt [55] . In this work, we found that JAK1 (Fig. 5E ) and JAK2 (Fig. 5D) were responsible for OSM-induced STAT3 phosphorylation at Tyr-705, whereas ERK1/2 mediated Ser-727 phosphorylation (Fig. 5D ). ERK1/2 also participated in the phosphorylation of CREB (Fig. 8B) . Akt, however, may not be involved in OSM-induced STAT3 phosphorylation at Ser-727 because OSM failed to affect Akt phosphorylation in cortical cultures ( Supplementary Fig. 3A) . Similarly, JNK is not important for the observed OSM effects because its phosphorylation was unaffected by OSM, at least within the first 60 min ( Supplementary  Fig. 3B ), and its inhibitor SP600125 was not effective in attenuating OSM-induced Mcl-1 expression ( Supplementary Fig. 3C ).
Although STAT3 inhibitor stattic completely inhibited OSM-induced Mcl-1 expression (Fig. 6C) , we found that STAT3 siRNA only partially suppressed OSM-induced Mcl-1 expression (Fig. 6E ) and neuroprotection (Fig. 6F, G) . At present, our findings suggest that STAT3 is necessary for OSM-mediated Mcl-1 induction and neuroprotection. Whether activation of STAT3 alone is sufficient for the Mcl-1 induction and 3-NP resistance requires further investigation. Given the involvements of STAT1 (Fig. 7) and CREB (Fig. 8 ) in addition to STAT3 (Figs. 5 and 6 ), it appears reasonable to observe only partial abolishment of OSMmediated neuroprotection when the corresponding inhibitor against STAT3, STAT1, or CREB was individually applied to cortical cultures during the preconditioning phase. The interplay between STAT1, STAT3, and CREB as well as other possible factors in OSM-induced Mcl-1 expression and neuroprotection is still unclear. Furthermore, while the STAT3 siRNA completely abrogated OSM-induced expression of STAT3 proteins back to basal level as compared to the control cultures (Fig. 6D) , the presence of the phosphorylated, and hence activated, STAT3 was still evident after OSM treatment. Indeed, when normalizing the cellular level of phosphor-STAT3 at Tyr-705 to that of total STAT3, no significant difference between OSM-treated cultures with and without STAT3 siRNA transfection was observed (Fig. 6D) ; similar findings with phosphor-STAT3 at Ser-727 were observed (Fig. 6D and quantitative data not shown). These findings indicate that, while siRNA is efficacious in attenuating STAT3 expression, it cannot completely eliminate the presence of phosphor-STAT3 because the residual STAT3 proteins are still subject to phosphorylation by JAK1, JAK2, and ERK1/2, which may explain the partial inhibitory effects of STAT3 siRNA on OSM-mediated Mcl-1 induction (Fig. 6E ) and possibly neuroprotection against 3-NP toxicity (Fig. 6F, G) .
So far, the only one study revealing Mcl-1 as one of the downstream target genes inducible by OSM was based on DNA microarray, which was conducted in osteosarcoma cells [36] . The underlying molecular mechanisms were not characterized in that report. Mcl-1 is traditionally known as an anti-apoptotic protein that may have neuroprotective functions. For example, overexpression of Mcl-1 reduces the progression of age-related cochlear dysfunction and sensory cell death by suppressing cochlear apoptosis at the mitochondrial level [56] . Parkin, encoded by PARK2 that is the most frequently mutated gene in hereditary Parkinson's disease, suppresses apoptosis of dopaminergic neurons in response to oxidative stress via stabilizing Mcl-1 [57] . Using primary cultures of cerebellar granule neurons deprived of serum and potassium as a model system, it has been demonstrated that ubiquitination and subsequent degradation of Mcl-1 initiate apoptosis [58] . In current study, we showed that Mcl-1 is the critical mediator for OSMdependent protection against 3-NP-induced mitochondrial dysfunction and neuronal death. In addition to the remarkable neuroprotective effects of OSM against 3-NP, we also observed that preconditioning with 100 ng/ml OSM for 24 h modestly conferred neuronal resistance against Aβ25-35 toxicity (Supplementary Fig. 1A ). It should be noted that we did not optimize the protective conditions of OSM for Aβ25-35 as this is beyond the scope of the present study. Nevertheless, this partial protective effect of OSM against Aβ25-35, unlike 3-NP, does not involve Mcl-1 ( Supplementary Fig. 1B ). These results indicated that OSM may trigger diversified defense mechanisms and, given the different pathological mechanisms of 3-NP [59] [60] [61] and Aβ25-35 [35, 62, 63] , it is possible that Mcl-1 may not be the only downstream molecule mediating OSM-dependent neuroprotection. Additional components contributing to the observed OSM effects await identification.
In our paradigm, OSM specifically induced expression of Mcl-1 without affecting expression of the anti-apoptotic Bcl-2 ( Supplementary  Fig. 2A ) and Bcl-xL ( Supplementary Fig. 2B ). Neither did OSM modulate the extents of cleaved caspase-3 associated with 3-NP exposure ( Supplementary Fig. 2C ), thus excluding the caspase-dependent apoptotic pathway as a prime target of Mcl-1. These findings led to the important question of how OSM and its downstream mediator Mcl-1 protect cortical neurons from 3-NP. Given the inhibitory effects of 3-NP on the mitochondrial complex II with resultant ATP depletion, it appeared reasonable to investigate the potential impact of OSM on Fig. 9 . Effects of OSM on mitochondrial respiratory function and the involvement of Mcl-1. Cultures were incubated in 100 ng/ml OSM for 24 h followed by replacement of fresh neurobasal medium supplemented with B27 for additional 4 h. One representative measurement of OCR is shown in (A). Various bioenergenic indices for mitochondrial function, including basal respiration (B), maximal respiration (C), spare respiratory capacity (D), ATP production (E), and non-mitochondrial respiration (F; Non-mito respiration) were conducted and calculated as described in Materials and methods. Mean ± S.E.M. from N = 10-12 out of 4 different cultures. * denotes P b 0.05. The "ns" denotes "not significant". (G, H) The experimental conditions were the same as described in (A-F) except that, prior to OSM pretreatment, cortical cultures were transfected with 1 μM Mcl-1 siRNA or sc siRNA for 72 h during DIV4-7. The effects of OSM and Mcl-1 knockdown on spare respiratory capacity (G) and ATP production (H) are shown. Mean ± S.E.M. from N = 5-7 out of 3 different cultures. * and # denote P b 0.05. The "ns" denotes "not significant". bioenergetics in cortical neurons. Our results demonstrated that OSM preconditioning significantly enhanced basal respiration rate, maximal respiration, spare respiration capacity, and ATP production without affecting non-mitochondrial respiration (Fig. 9A-F) . Several studies have demonstrated that the neuroprotective efficacy of various reagents may rely on their capabilities of restoring mitochondrial bioenergetics. For example, in PC12 cells challenged with 3-NP, treatment with Psoralea corylifolia Linn seed extracts significantly stimulated mitochondrial respiration and increased bioenergetic reserve capacity, thereby leading to restoration of ATP levels and attenuation of cell death [30] . Pretreatment of magnesium sulfate also protects a selective population of primary cortical neurons against glutamate-induced loss of spare respiratory capacity [64] . Indeed, spare respiratory capacity, rather than oxidative stress, regulates glutamate excitotoxicity after partial respiratory inhibition of mitochondrial complex I with rotenone in rat cerebellar granule neurons [47] . These previous and our own studies indicate that selected protective reagents may rescue neurons from mitochondrial dysfunction via restoration of bioenergetics without affecting caspase-dependent apoptotic mechanisms. Intriguingly, to our best knowledge this is the first study reporting the capability of OSM, a cytokine belonging to the IL-6 family, in boosting mitochondrial respiration rate with increased ATP production. This effect is specific to OSM as preconditioning of cortical neurons with BDNF did not enhance ATP production (Wu and Yang, unpublished observations).
Downstream of OSM, siRNA-mediated knockdown experiments confirmed that Mcl-1 in part contributed to the increases in spare respiratory capacity (Fig. 9G ) and ATP production (Fig. 9H) . While the underlying mechanisms remain obscure, one recent study reported that Mcl-1 can be imported into the mitochondrial matrix to facilitate normal mitochondrial fusion, ATP production, respiration, and maintenance of oligomeric ATP synthase; further, deletion of Mcl-1 decreases both basal and maximal OCRs as well as cellular ATP contents in murine embryonic fibroblasts [11] . These results are consistent with our own findings that Mcl-1 induced by OSM contributes to enhancement of mitochondrial bioenergetics. In addition to Mcl-1, OSM also activates transcription of long-chain acyl-coenzymeA (CoA) synthetase isoforms 3 and 5 (ACSL3, ACSL5) in the livers of hamsters, which are associated with decreased triglyceride accumulation and increased fatty acid β-oxidation [65] . While the extent of ATP production was not measured in that study, it is tempting to speculate that enhanced β-oxidation of fatty acids likely results in increased ATP synthesis. Finally, other mechanisms not directly related to ATP production should also be considered. For example, since deletion of Mcl-1 in post-mitotic cortical neurons may increase autophagic responses [66, 67] , possible involvement of autophagy in mediating OSM-and Mcl-1-dependent neuroprotective effects remains to be a possibility and awaits further investigation.
In conclusion, we have demonstrated the neuroprotective actions of OSM preconditioning against mitochondrial inhibition in response to 3-NP exposure. We also revealed a novel and complex signal cascade involving JAK1, JAK2, ERK1/2, STAT1, STAT3, and CREB as well as their target Mcl-1 that together contribute to OSM-dependent neuroprotective effects against mitochondrial dysfunction commonly associated with neurodegeneration. Furthermore, we found that OSM-dependent Mcl-1 induction in part contributes to the enhancements of mitochondrial bioenergetics in primary cortical cultures. Administration of OSM to animal models mimicking neurodegenerative disorders for the studies of its therapeutic potential warrants further investigation.
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